Biotech IPOs Rebound...But Where's BioRx?
Executive Summary1995 has witnessed a startling turnaround in the biotech public equity market, but while biotech IPOs haven’t reached these levels since the financing window of 1991-92, they don’t look like they used to. As the chart below illustrates, today’s biotech IPO investor tends to favor biodiagnostic companies and companies selling drug development services.
You may also be interested in...
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.